|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
|
30850499 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-DKFZ-PSMA-617 radionuclide therapy is a safe and effective approach in the treatment of mCRPC patients.
|
27506431 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (<sup>177</sup>Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC).
|
30683770 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-PSMA-617 (Lu-PSMA) is an emerging therapy in men with metastatic castration-resistant prostate cancer.
|
30425003 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup> Ga-PSMA PET/CT shows more lesions than bone scans, but data on diagnostic performance are very limited and indicate improved diagnostic performance in primary staging but not in mCRPC.
|
29082604 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT for monitoring response to <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
|
30697649 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
|
31689280 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
|
31693627 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer.
|
27660138 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
|
29026946 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA)-targeted therapy with <sup>177</sup>Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
29651569 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) targeting alpha-radiation therapy (TAT) is an emerging treatment modality for metastatic castration-resistant prostate cancer.
|
31601699 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
|
31742767 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC).
|
31831560 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A retrospective investigation of men with mCRPC undergoing evaluation at medical oncology clinics at our institution assessed the dynamics of PSMA expression in the context of different systemic treatments administered sequentially.
|
31361358 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
28083690 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ac-based PSMA-targeted therapy has emerged as promising agent for the treatment of metastatic castration-resistant prostate cancer.
|
30932973 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the use of PSMA tracers in systemic radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC), as well as non-prostatic specific uptake of PSMA tracers and the use of PSMA imaging to manage therapy have been described.
|
28217987 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on these promising preclinical results, <sup>152</sup>Tb was shipped to Zentralklinik Bad Berka, Germany, where it was used for labeling of PSMA-617, enabling PET imaging of a patient with mCRPC.
|
31346796 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined Ga-PSMA-617 PET imaging and Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
30985422 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
|
31789908 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
|
31587172 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
|
27922871 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
|
30829871 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
First-in-human study of <sup>177</sup>Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
|
30090965 |
2019 |